

CITATION REPORT

List of articles citing

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

DOI: 10.1038/s41591-022-01977-y

»»»

Source: <https://exaly.com/paper-pdf/150267775/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis.		0
20	Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas.		0
19	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. 2022 , 14, 6145		0
18	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023 ,		0
17	Response to Immune Checkpoint Inhibitors Is Affected by Deregulations in the Antigen Presentation Machinery: A Systematic Review and Meta-Analysis. 2023 , 12, 329		0
16	Immunotherapy-based combinations in metastatic NSCLC. 2023 , 116, 102545		0
15	Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. 2023 , 179, 107173		0
14	Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report. 13,		0
13	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. 2023 , 11, 508		0
12	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. 2023 , 30, 2366-2387		0
11	MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. 2023 ,		0
10	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. 2023 , 12, 1833		0
9	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions.		0
8	Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). 2023 , 8, 101192		0
7	Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. 2023 ,		0
6	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1.		0
5	Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?.		0

- 4 The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer. **2023**, 15, 2319 ○
- 3 Emerging evidence and treatment paradigm of non-small cell lung cancer. **2023**, 16, ○
- 2 Identifying optimal first-line immune checkpoint inhibitors based regimens for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis. **2023**, 18, e0283719 ○
- 1 Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer. 13, ○